FDA Approves Mavorixafor Capsules to Treat Patients With WHIM Syndrome

The indication is for patients aged 12 years of age and older, and the treatment is intended to increase the number of mature neutrophils and lymphocytes in patients.

Related Keywords

Teresak Tarrant ,Paula Ragan ,Pharmaceuticals Announces ,Duke University School Of Medicine ,Deficiency Foundation ,Jorey Berry ,Immune Deficiency Foundation ,Safety Study ,Participants With Warts ,Duke University School ,First Drug Indicated ,Syndrome Clinicaltrials ,